Navigation Links
FDA Adds More Warnings to Antidepressant's Label
Date:3/28/2012

WEDNESDAY, March 28 (HealthDay News) -- In a follow-up to a warning that high doses of the popular antidepressant Celexa can cause potentially fatal abnormal heart rhythms, the U.S. Food and Drug Administration has issued new dosing and use recommendations.

Last August, the FDA said doses of Celexa (citalopram hydrobromide) greater than 40 milligrams a day can cause changes in the electrical activity of the heart, which can lead to abnormal heart rhythms, including a potentially deadly arrhythmia known as Torsade de Pointes.

Patients at high risk include those with preexisting heart conditions (including congestive heart failure) and those prone to low levels of potassium and magnesium in the blood, the FDA said.

At the time, the drug label was revised to include the new dosage limit as well as information about the potential for abnormal heart electrical activity and rhythms.

The latest recommendations note that Celexa in any dose should not be given to patients with certain conditions due to the risk of suffering these heart problems. However, it may be important for some patients to take Celexa, so the label has been changed to describe the particular cautions required when giving the drug to these patients.

Here are the latest FDA recommendations:

  • Celexa should not be used at doses greater than 40 milligrams (mg).
  • Celexa is not recommended for use in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent heart attack, or uncompensated heart failure.
  • Use of the Celexa is also not recommended in patients who are taking other drugs that prolong the QT interval, a measure of a heart's electrical activity.
  • The maximum recommended dose of Celexa is 20 mg per day for patients with liver impairment, patients who are older than 60, patients who are CYP 2C19 poor metabolizers, or patients who are also taking cimetidine (Tagamet) or another CYP 2C19 inhibitor. All of these factors lead to increased blood levels of Celexa, increasing the risk of QT interval prolongation and Torsade de Pointes, the FDA said.

Dr. Norman Sussman, a psychiatrist at NYU Langone Medical Center and a professor at NYU School of Medicine in New York City, said: "What the FDA's recommendations ultimately mean is that before prescribing, after prescribing and especially when considering starting a new drug, a physician in any specialty who is treating a patient taking citalopram should be certain of the effect the medication may have on the QT interval.

"These recommendations are basically a game changer for the way in which citalopram should be prescribed, and how patients taking citalopram should be monitored," he said.

Celexa belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), which also include widely used medications such as Paxil, Prozac and Zoloft.

More information

The American Academy of Family Physicians has more about antidepressants.

-- Robert Preidt

SOURCEs: Norman Sussman, psychiatrist, NYU Langone Medical Center, and professor, NYU School of Medicine, New York City; U.S. Food and Drug Administration, news release, March 28, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. U.S. Will Push to Have Graphic Warnings on Cigarettes
2. Judge Blocks Plan for Graphic Cigarette Warnings
3. Judge Blocks FDA Plan for Graphic Cigarette Warnings
4. FDA Proposes Graphic Warnings on Cigarette Packs
5. FDA Calls for New Warnings on Some Prostate Cancer Drugs
6. Does the brain remember antidepressants?
7. Moms Antidepressants May Affect Babies Head Size: Study
8. Antidepressants While Pregnant Linked to Slight Risk of Lung Problem in Babies
9. Blood test might predict how well a depressed patient responds to antidepressants
10. Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients
11. Fear of Antidepressants Keep Many From Disclosing Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... Maryland’s soybean farmers have improved ... released by the United Soybean Board. , Thanks to the responsible use ... their productivity on less land per bushel, the report says. The United Soybean ...
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... Viejo, CA (PRWEB) , ... June 25, 2017 , ... ... any media into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 ... add film grain for distorted looks, vignettes and blurs to single out subjects, plus ...
(Date:6/25/2017)... ... , ... An increase in wetter weather in the Northern California area naturally ... a humdinger of an allergy season. A relief from drought conditions is most welcome, ... and weed pollen. , “Our patients have been reporting the typical allergy season ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus ... cancer among men in the U.S. and the third most common cause of cancer related ... one man in seven will be diagnosed with prostate cancer during his lifetime. Those ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
(Date:6/5/2017)... 5, 2017 Kohll,s Pharmacy & Homecare is the first ... United States . The Raizer is a simple battery ... up to an almost-standing position within a few ... one assistant and does not require any extra effort ... a child can operate it, and lightweight and ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
Breaking Medicine Technology: